Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...
Telix Pharmaceuticals Program Update Q3 2019
MELBOURNE (Australia) – Nov. 4, 2019 - Telix Pharmaceuticals Ltd Program Update Q3, 2019
Telix Pharmaceuticals to Acquire European Production Facility
MELBOURNE (Australia) and BRUSSELS (Belgium) – Oct. 3, 2019 - Telix Pharmaceuticals Ltd is pleased to announce that it has...
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
Melbourne and Adelaide (Australia) – 30 October 2019. Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered...